| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 142.59 | 3547 |
| Intrinsic value (DCF) | 9576.14 | 244814 |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
Dominari Holdings Inc. (NASDAQ: DOMH) is a biotechnology company focused on developing innovative small-molecule anti-cancer therapeutics and antiviral treatments. The company's pipeline includes promising candidates such as DHA-dFdC for pancreatic cancer and KPC34 for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Additionally, Dominari is advancing an antiviral platform targeting viruses like influenza, Ebola, and SARS-CoV-2. With strategic license agreements from leading institutions such as the University of Texas and Wake Forest University, Dominari leverages cutting-edge research to address unmet medical needs in oncology and virology. Formerly known as AIkido Pharma Inc., the company rebranded in December 2022 to reflect its evolving focus on transformative therapies. Headquartered in New York, Dominari operates in the high-growth biotechnology sector, positioning itself as a potential disruptor in precision medicine and antiviral innovation.
Dominari Holdings presents a high-risk, high-reward investment opportunity in the biotechnology sector. The company's focus on oncology and antiviral therapeutics aligns with growing demand for targeted cancer treatments and pandemic preparedness. However, with a market cap of ~$67M, negative earnings (EPS -$2.38), and operating cash flow challenges (-$15.1M), the stock is speculative. Investors must weigh the potential of its clinical pipeline against the inherent risks of biotech development, including regulatory hurdles and funding needs. The company's partnerships with academic institutions add credibility, but commercialization remains distant. Suitable for risk-tolerant investors with a long-term horizon.
Dominari Holdings operates in the highly competitive oncology and antiviral biotechnology space, where it faces competition from both large pharmaceutical firms and specialized biotech companies. Its competitive advantage lies in its niche focus on small-molecule therapies and strategic academic collaborations, which may accelerate R&D. However, the company's early-stage pipeline and limited financial resources put it at a disadvantage against well-capitalized peers with approved products. Dominari's antiviral platform could differentiate it if successfully developed, given the increased global focus on pandemic preparedness. The company's ability to advance KPC34 and DHA-dFdC through clinical trials will be critical in establishing its position. While its market cap is small compared to industry leaders, successful trial results or partnerships could significantly enhance its valuation. The main challenge is securing sufficient funding to reach key milestones without excessive dilution.